FLAGSTAFF, Ariz. (August 19, 2021) — W. L. Gore & Associates (Gore), today announced that five-year results of the U.S. prospective, multicenter study (N = 63) of endovascular repair of iliac aneurysms using the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) were presented at the 2021 Society for Vascular Surgery Annual Meeting. Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.

FLAGSTAFF, Ariz. (APRIL 12, 2022) — Gore Medical has received Breakthrough Device designation from the U.S. Food and Drug Administration for the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device). The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The TAMBE Device is the third Breakthrough Device in the company’s aortic endovascular portfolio to date, following the GORE® TAG® Thoracic Branch Endoprosthesis and the GORE® Ascending Stent Graft, two other investigational devices being developed.

FLAGSTAFF, Ariz. (March 11, 2021)— W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England Journal of Medicine (NEJM), highlighting the benefits of patent foramen ovale (PFO) closure. The extended follow-up data further supports the use of GORE CARDIOFORM Septal Occluder in long-term recurrent stroke prevention.